BeOne Medicines (ONC) Earnings Date & Reports

Key Takeaways

• Analysts expect Q1 2026 revenue of $1.44 billion, reflecting continued expansion from blockbuster BRUKINSA (BTK inhibitor) sales.
• Consensus EPS estimate stands at $0.82 per ADS, building on the company's first full year of GAAP profitability in 2025.
• Q4 2025 results showed $1.5 billion in revenue (beat estimates) but GAAP EPS of $0.58 (missed $1.60), with shares dropping post-release due to guidance.
• Full-year 2026 revenue guidance of $6.2–$6.4 billion signals 16–20% growth over 2025's $5.3 billion.
• Investors watching BRUKINSA global uptake, TEVIMBRA (tislelizumab) reimbursement progress, and pipeline readouts in hematology and solid tumors.
• Fiscal year ends December 31; Q1 covers January–March 2026, with release expected late April or early May.

Earnings Context and Why It Matters

BeOne Medicines AG (ONC), a global oncology leader formerly known as BeiGene, has transformed into a revenue powerhouse with BRUKINSA establishing dominance in the BTK inhibitor (BTKi) class for cancers like chronic lymphocytic leukemia (CLL). After achieving GAAP profitability in 2025 with $5.3 billion in revenue (up 40% YoY), Q1 2026 earnings will test sustained momentum amid competition and reimbursement dynamics. For investors, this report offers insights into ex-China growth, margin expansion from manufacturing efficiencies, and guidance updates critical for valuing the deep pipeline. In a biotech sector facing patent cliffs, ONC's shift to sustainable profitability underscores its appeal.

Earnings Expectations

Wall Street anticipates Q1 2026 revenue of $1.44 billion, up from $1.12 billion in Q1 2025, driven by BRUKINSA (49% FY2025 growth to $3.9 billion) and TEVIMBRA adoption. Consensus GAAP diluted EPS is $0.82 per American Depositary Share (ADS), improving from prior losses, with 9 analysts contributing. Key metrics include product revenues (99% of total in Q4 2025) and operating cash flow, which hit $1.1 billion for FY2025.

Historically, ONC has mixed beats: Q4 2025 revenue topped $1.45 billion estimates at $1.50 billion (+33% YoY), but GAAP EPS missed ($0.58 vs. $1.60), while non-GAAP hit $1.95 (beat $1.53). Stock fell ~8.5% the next day to $322, pressured by 2026 guidance midpoint below consensus, though analysts like Bernstein stayed bullish (Outperform, $414 PT). Watch for updates on BTKi leadership, TEVIMBRA labels, and cash ($4.5 billion at YE2025).

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions in dynamic markets like biotech. Explore it today to uncover potential plays similar to ONC.

Market Reaction and Investor Sentiment

Heading into Q1 earnings (est. late April/early May), sentiment is cautiously optimistic after Q4's revenue beat offset by EPS miss and soft guidance, causing an ~8-12% share drop. Risks include BTKi competition (e.g., pirtobrutinib), China reimbursement delays, and R&D spend on 15,800+ trial patients. Upside from pipeline (e.g., CaDAnCe-304 CLL study) and $4.5 billion cash supports buy ratings (avg. PT $408), but volatility persists in oncology.

Forward Outlook and Key Factors to Monitor

Post-Q1, focus shifts to 2026 guidance execution ($6.2–$6.4 billion revenue, $700–$800 million GAAP operating income), implying mid-teens growth from BRUKINSA's global leadership and TEVIMBRA expansions.

Pipeline catalysts include head-to-head CLL data vs. pirtobrutinib, tislelizumab combos (5,000+ ex-China patients), and Fast Track for BGB-B2033 in hepatocellular carcinoma (HCC). Manufacturing ramps in Switzerland/China bolster margins.

Demand signals from U.S. volume growth (~30% Q4) and emerging markets matter, alongside cost trends like R&D (deep pipeline) and debt ($1 billion vs. $4.5 billion cash). Industry headwinds: pricing pressures, biosimilars. Balanced view: profitability milestone aids valuation, but execution on labels/reimbursement key.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations